Development and comparison of intramuscularly long-acting paliperidone palmitate nanosuspensions with different particle size

International Journal of Pharmaceutics

Volumn 472, Issue 1-2, 2014, Pages 380-385

  Leng, Donglei ^a   Chen, Hongming ^a   Li, Guangjing ^a   Guo, Mengran ^a   Zhu, Zhaolu ^a   Xu, Lu ^a   Wang, Yongjun ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Nanosuspensions; Paliperidone palmitate; Particle size; Pharmacokinetics

Indexed keywords

NANOPARTICLE; NANOSUSPENSION; PALIPERIDONE; UNCLASSIFIED DRUG; DELAYED RELEASE FORMULATION; ISOXAZOLE DERIVATIVE; PALMITIC ACID DERIVATIVE; SUSPENSION;

ACCURACY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BEAGLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STORAGE; EXPERIMENTAL DOG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SYSTEMIC CIRCULATION; THERMOGRAPHY; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY POWDER DIFFRACTION; ZETA POTENTIAL; ANIMAL; BLOOD; CHEMISTRY; DELAYED RELEASE FORMULATION; DOG; INTRAMUSCULAR DRUG ADMINISTRATION; SOLUBILITY; SUSPENSION; ULTRASTRUCTURE; X RAY DIFFRACTION;

ANIMALS; CALORIMETRY, DIFFERENTIAL SCANNING; DELAYED-ACTION PREPARATIONS; DOGS; INJECTIONS, INTRAMUSCULAR; ISOXAZOLES; MALE; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PALMITATES; PARTICLE SIZE; SOLUBILITY; SUSPENSIONS; X-RAY DIFFRACTION;

EID: 84904803520     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.05.052     Document Type: Article

References (23)

1. D. Bishara Once-monthly paliperidone injection for the treatment of schizophrenia Neuropsychiatr. Dis. Treat. 6 2010 561 572
2. B.H.L. Böhm, and R.H. Müller Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs Pharm. Sci. Tech. Today. 2 1999 336 339 (Pubitemid 29378538)
3. L. Gao, G. Liu, J. Ma, X.Q. Wang, L. Zhou, and X. Li Drug nanocrystals: in vivo performances J. Control. Release 160 2012 418 430
4. L. Gao, G. Liu, X. Wang, F. Liu, Y. Xu, and J. Ma Preparation of a chemically stable quercetin formulation using nanosuspension technology Int. J. Pharm. 404 2011 231 237
5. S. Gopal, C. Gassmann-Mayer, J. Palumbo, M.N. Samtani, R. Shiwach, and L. Alphs Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia Curr. Med. Res. Opin. 26 2010 377 387
6. D. Hough, S. Gopal, U. Vijapurkar, P. Lim, M. Morozova, and M. Eerdekens Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study Schizophr. Res. 116 2010 107 117
7. C. Jacobs, O. Kayser, and R.H. Müller Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide Int. J. Pharm. 196 2000 161 164 (Pubitemid 30105734)
8. Janssen-Ortho Inc., 2010. Invega Sustenna. Product Monograph (revised 21.07.10).
9. S.J. Keith, J.M. Kane, M. Turner, R.R. Conley, and H.A. Nasrallah Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics J. Clin. Psychiatry 65 2004 120 131
10. M. Kramer, G. Simpson, V. Maciulis, S. Kushner, U. Vija purkar, P. Lim, and M. Eerdekens Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study J. Clin. Psychopharmacol. 27 1 2007 6 14 (Pubitemid 46105757)
11. K.P. Krause, and R.H. Müller Production and characterisation of highly concentrated nanosuspensions by high pressure homogenisation Int. J. Pharm. 214 2001 21 24 (Pubitemid 32244072)
12. A. Kwade Wet comminution in stirred media mills-research and its practical application Powder Technol. 105 1999 14 20 (Pubitemid 29531589)
13. G.P. Liu, D.R. Zhang, Y. Jiao, H.J. Guo, D.D. Zheng, L.J. Jia, C.X. Duan, Y. Liu, X.N. Tian, J.Y. Shen, C.Y. Li, Q. Zhang, and H.X. Lou In vitro and in vivo evaluation of riccardin D nanosuspensions with different particle size Colloids Surf. B: Biointerfaces 102 2013 620 626
14. J.P. McEvoy Risks versus benefits of different types of long-acting injectable antipsychotics J. Clin. Psychiatry 67 2006 15 18 (Pubitemid 43837697)
15. A.A. Megens, and F.H.L. Awouters In vivo pharmacological profile of 9-hydroxyris-peridone the major metabolite of the novel antipsychotic risperidone Drug. Dev. Res. 33 1994 399 412
16. R.H. Müller, and A. Akkar Drug nanocrystals of poorly soluble drugs Encycl. Nanosci. Nanotechnol. 2 2004 627 638
17. R.H. Müller, C. Jacobs, and O. Kayser Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future Adv. Drug Deliv. Rev. 47 2001 3 19 (Pubitemid 32209229)
18. R.H. Müller, and K. Peters Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique Int. J. Pharm. 160 1998 229 237 (Pubitemid 28083096)
19. H.A. Nasrallah The case for long-acting antipsychotic agents in the post-CATIE era Acta. Psychiatr. Scand. 115 2007 260 267 (Pubitemid 46425751)
20. Paliperidone palmitate prescribing information, 2009. http://www.invegasustenna.com/invegasustenna/shared/pi/invegasustenna.pdf (accessed november 2009).
21. M. Sarkari, J. Brown, X. Chen, S. Swinnea, R.O. Williams III, and K.P. Johnston Enhanced drug dissolution using evaporative precipitation into aqueous solution Int. J. Pharm. 243 2002 17 31
22. D.I. Velligan, P.J. Weiden, M. Sajatovic, J. Scott, D. Carpenter, R. Ross, and J.P. Docherty The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness J. Clin. Psychiatry 70 2009 1 46
23. Vermeule, A., Wouters, A., 2009. Dosing regimen association with long acting injectable paliperidone esters. US20090163519A.